IP Library Granted Patent US 9,440,986
Granted Patent B2
US 9,440,986 · App. 14/613,421 · Granted Sep 13, 2016

Crystalline, anhydrous forms of oxymorphone hydrochloride

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,440,986
App. No.
14/613,421
Granted
Sep 13, 2016
Kind
B2
Abstract

Crystalline, anhydrous hydrochloride salts of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one (oxymorphone) are disclosed and three polymorphic forms of these salts are reported. The invention further relates to a method for the production of such salts, a pharmaceutical composition comprising an effective amount of such a salt and such a salt as a medicament and for the treatment and/or prevention of pain.

Claims (18)

1. A crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one according to formula (I):

wherein the hydrochloride salt exhibits an X-ray powder diffractogram wherein peaks are observed at a grouping of peaks selected from the group consisting of A and B:

A) at (±0.2 in 2θ): 9.2, 12.7, 13.8, 14.7, 15.3, 16.2, 17.1, 19.0, 19.9, 20.6, 21.7, 24.6, 31.9 and 34.6; and

B) (±0.2 in 2θ): 6.0, 12.1, 13.1, 13.6, 15.3, 16.5, 22.4, 22.6, 24.1 and 29.8.

2. The hydrochloride salt according to claim 1 , wherein the melting or sublimation temperature, defined as the peak temperature in a differential scanning calorimetry measurement at a heating rate of 10° C./minute, is ≧250° C.

3. A method for the preparation of a crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I) according to claim 1 , comprising the steps of:

providing a hydrate hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I); and

heating to a temperature of ≧130° C. to ≦210° C.

4. The method according to claim 3 , further comprising the step of grinding the hydrate hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I) prior to heating.

5. The method according to claim 3 , wherein the heating is conducted during a hot-melt extrusion process.

6. A pharmaceutical composition comprising an effective amount of a crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I) according to claim 1 .

7. A method of treating and/or inhibiting pain in a patient in need of such treatment, said method comprising administering to said patient an effective amount therefor of a crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I) according to claim 1 .

8. The pharmaceutical composition of claim 6 , wherein the effective amount of a crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one is from about 0.05 mg/kg to about 500 mg/kg of body weight of a patient.

9. The pharmaceutical composition of claim 6 , wherein the composition is a delayed release composition.

10. The pharmaceutical composition of claim 6 , wherein the composition is a controlled release composition.

11. The pharmaceutical composition of claim 6 , wherein the composition is used with at least one other pharmaceutical active substance.

12. A method of treating pain in a subject in need thereof, said method comprising administering to said subject an analgesically effective amount of the crystalline, anhydrous hydrochloride salt of 4,5α-epoxy-3,14-dihydroxy-17-methylmorphinan-6-one of formula (I) according to claim 1 .

13. The hydrochloride salt according to claim 1 , wherein the melting or sublimation temperature, defined as the peak temperature in a differential scanning calorimetry measurement at a heating rate of 10° C./minute, is from about 280° C. to about 290° C.

Assignments (6)
SECURITY INTEREST Recorded Jul 22, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: COMPUTERSHARE TRUST COMPANY, NATIONAL ASSOCIATION
Reel/Frame 068469/0001 →
SECURITY INTEREST Recorded Jul 19, 2024
From: ENDO BIOLOGICS LIMITED; ENDO OPERATIONS LIMITED
To: GOLDMAN SACHS BANK USA
Reel/Frame 068461/0692 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 27, 2024
From: ENDO USA, INC.
To: ENDO OPERATIONS LIMITED
Reel/Frame 067245/0492 →
RELEASE OF SECURITY INTEREST Recorded Apr 26, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH HOLDINGS, LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO GENERIC HOLDINGS, INC. (FORMERLY KNOWN AS PAR PHARMACEUTICALS COMPANIES, INC.); ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067240/0001 →
RELEASE OF SECURITY INTEREST Recorded Apr 25, 2024
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: ACTIENT PHARMACEUTICALS LLC; ASTORA WOMEN’S HEALTH LLC; AUXILIUM PHARMACEUTICALS, LLC; AUXILIUM US HOLDINGS, LLC; BIOSPECIFICS TECHNOLOGIES CORP.; BIOSPECIFICS TECHNOLOGIES LLC; DAVA INTERNATIONAL, LLC; DAVA PHARMACEUTICALS, LLC; ENDO PHARMACEUTICALS INC.; ENDO PHARMACEUTICALS SOLUTIONS INC. (FORMERLY KNOWN AS INDEVUS PHARMACEUTICALS, INC.); GENERICS BIDCO I, LLC; GENERICS INTERNATIONAL (US), INC.; PAR PHARMACEUTICAL, INC.; PAR PHARMACEUTICAL COMPANIES, INC.; PAR STERILE PRODUCTS, LLC (FORMERLY KNOWN AS JHP PHARMACEUTICALS, LLC); QUARTZ SPECIALTY PHARMACEUTICALS, LLC; SLATE PHARMACEUTICALS, LLC; VINTAGE PHARMACEUTICALS, LLC
Reel/Frame 067239/0491 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 23, 2024
From: ENDO PHARMACEUTICALS INC.
To: ENDO USA, INC.
Reel/Frame 067203/0398 →